As part of the three-year deal, several collaborative studies will be conducted in tumor types such as gastroesophageal adenocarcinoma, pancreatic adenocarcinoma and hepatocellular carcinoma. Under the deal, the
As part of the deal, CMC will develop a CHEF1 production cell line and process for manufacture of MVI’s monoclonal antibody, targeting circumsporozoite protein (CSP), for use by
SinoVeda Canada has signed an exclusive license agreement with Exzell Pharma to commercialize Effecti-Cal in Canada, the US, Australia and New Zealand. The agreement includes upfront and milestone
Earlier in January, the company entered into a world-wide collaboration with UCB to develop and commercialize NPT200-11 in all indications. So far, the company has secured $20.5m of
The trial met its primary endpoint, showing that venetoclax monotherapy resulted in a clinically meaningful reduction in the number of cancer cells in a pre-defined proportion of people
Vonapanitase is an investigational drug that may prolong the patency and reduce the failure of hemodialysis vascular access in patients with CKD. The new trial complements the first
The earlier collaboration between the two firms focused on the discovery of new treatments for neuropsychiatric disorders, while the new three-year deal will focus on investigating new medicines
HD is caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the
Brintellix was discovered by Lundbeck researchers and the clinical trial program in the US was conducted jointly by the two firms, while Takeda holds the NDA for the
Both the firms will collaborate on seeking regulatory approval from Australia’s Therapeutic Goods Administration (TGA) and New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe). As part of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.